{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:30:09Z","timestamp":1792078209903,"version":"4.4.0"},"reference-count":31,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tirzepatide has demonstrated substantial weight\u2010loss efficacy in clinical trials, but real\u2010world evidence from routine digital prescribing remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study of adults initiating tirzepatide for obesity via a UK digital prescribing service between March 2024 and July 2025. Linked order\u2010level prescribing data and self\u2010reported weights were analysed to estimate percentage weight change at 3, 6, 9, and 12\u2009months. Adherence was assessed using mean days between medication orders. A 6\u2010month survey captured patient\u2010reported outcomes including lifestyle changes and side effects. The primary endpoint was percentage weight change at 6\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Following analysis of 630\u2009545 eligible patients (80.3% female, mean BMI 36.1\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      [SD 5.8]), mean weight loss in those with recorded weights was \u221213.5% (95% CI: \u221213.56 to \u221213.51) at 6\u2009months (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009270\u2009309) and \u221217.4% (95% CI: \u221217.5 to \u221217.3) at 12\u2009months (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200958\u2009434). At 6\u2009months, 89.9% achieved \u2265\u20095% weight loss and 72.1% achieved \u2265\u200910%. More regular ordering cadence was associated with greater weight loss, and clinically meaningful outcomes were frequently achieved without escalation beyond intermediate doses. Treatment persistence was higher among patients from less deprived areas, with 26.1% more prescription orders than those from the most deprived areas. Patients reported improvements in mobility (46.7%) and mood (45.9%), and reduced alcohol consumption (26.7%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Tirzepatide was associated with substantial weight loss and significant patient\u2010reported benefits including mood and mobility improvement. Treatment continuity was a correlate of effectiveness, and maximal dose escalation was often unnecessary. These findings support the effective delivery of GLP\u20101 medication for the treatment of obesity via digital prescribing pathways.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.71067","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T12:40:47Z","timestamp":1786020047000},"page":"9621-9632","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real\u2010World Effectiveness and Treatment Patterns of Tirzepatide in a Large\n                    <scp>UK<\/scp>\n                    Digital Health Cohort"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6632-1331","authenticated-orcid":false,"given":"Onayomi","family":"Rosenior\u2010Patten","sequence":"first","affiliation":[{"name":"HeliosX Group  Leamington Spa Warwickshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5988-1049","authenticated-orcid":false,"given":"Zoe","family":"Lees","sequence":"additional","affiliation":[{"name":"HeliosX Group  Leamington Spa Warwickshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3395-2385","authenticated-orcid":false,"given":"Rebecca","family":"Rowe","sequence":"additional","affiliation":[{"name":"HeliosX Group  Leamington Spa Warwickshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8029-1092","authenticated-orcid":false,"given":"Safia","family":"Hussain","sequence":"additional","affiliation":[{"name":"HeliosX Group  Leamington Spa Warwickshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1359-9337","authenticated-orcid":false,"given":"Ehtasham","family":"Ahmad","sequence":"additional","affiliation":[{"name":"HeliosX Group  Leamington Spa Warwickshire UK"},{"name":"University Hospitals of Leicester NHS Trust  Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4036-8883","authenticated-orcid":false,"given":"Edward","family":"Brooke","sequence":"additional","affiliation":[{"name":"HeliosX Group  Leamington Spa Warwickshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7267-0239","authenticated-orcid":false,"given":"Sophie","family":"Dix","sequence":"additional","affiliation":[{"name":"HeliosX Group  Leamington Spa Warwickshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5860-3785","authenticated-orcid":false,"given":"Catriona","family":"Maybury","sequence":"additional","affiliation":[{"name":"HeliosX Group  Leamington Spa Warwickshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"World Health Organization \u201cObesity Geneva World Health Organization \u201d(2025) https:\/\/www.who.int\/health\u2010topics\/obesity."},{"key":"e_1_2_11_3_1","unstructured":"Office for Health Improvement and Disparities \u201cObesity Profile: Short Statistical Commentary May 2025 London UK Government \u201d(2025) https:\/\/www.gov.uk\/government\/statistics\/obesity\u2010profile\u2010may\u20102025\u2010update\/obesity\u2010profile\u2010short\u2010statistical\u2010commentary\u2010may\u20102025."},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-019-0176-8"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30288-2"},{"key":"e_1_2_11_6_1","unstructured":"J.Holmes \u201cTackling Obesity: The Role of the NHS in a Whole\u2010System Approach London the King's Fund \u201d(2021) https:\/\/assets.kingsfund.org.uk\/f\/256914\/x\/cead3911f6\/tackling_obesity_role_nhs_whole_system_approach_2021.pdf."},{"key":"e_1_2_11_7_1","unstructured":"Tony Blair Institute for Global Change \u201cUnhealthy Numbers: The Rising Cost of Obesity in the UK London Tony Blair Institute for Global Change \u201d(2023) https:\/\/institute.global\/insights\/public\u2010services\/unhealthy\u2010numbers\u2010the\u2010rising\u2010cost\u2010of\u2010obesity\u2010in\u2010the\u2010uk."},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15447"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(24)00316\u20104"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.14797\/mdcvj.1515"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.r1855"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.3399\/BJGP.2025.0610"},{"key":"e_1_2_11_13_1","unstructured":"National Institute for Health and Care Excellence (NICE) \u201cOverweight and Obesity Management (NICE Guideline NG246) London NICE \u201d(2025) https:\/\/www.nice.org.uk\/guidance\/ng246."},{"key":"e_1_2_11_14_1","unstructured":"National Institute for Health and Care Excellence (NICE) \u201cTirzepatide for Managing Overweight and Obesity (Technology Appraisal Guidance TA1026) London NICE \u201d(2024) https:\/\/www.nice.org.uk\/guidance\/ta1026."},{"key":"e_1_2_11_15_1","unstructured":"Tony Blair Institute for Global Change \u201cAnti\u2010Obesity Medications: Faster Broader Access Can Drive Health and Wealth in the UK London Tony Blair Institute for Global Change \u201d(2025) https:\/\/institute.global\/insights\/public\u2010services\/anti\u2010obesity\u2010medications\u2010faster\u2010broader\u2010access\u2010can\u2010drive\u2010health\u2010and\u2010wealth\u2010in\u2010the\u2010uk."},{"key":"e_1_2_11_16_1","unstructured":"C.MeyrickandP.Doshi \u201cSilver Bullet or Sticking Plaster? Weight\u2010Loss Drugs and the UK's Obesity Crisis London Nesta \u201d(2025) https:\/\/www.nesta.org.uk\/data\u2010visualisation\u2010and\u2010interactive\/silver\u2010bullet\u2010or\u2010sticking\u2010plaster\u2010weight\u2010loss\u2010drugs\u2010and\u2010the\u2010uks\u2010obesity\u2010crisis\/."},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-023-01198-4"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-025-01723-w"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.9217"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare14010060"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.2196\/83718"},{"key":"e_1_2_11_23_1","unstructured":"NHS England \u201cPolicy Guidance on Recording Patient Safety Events and Levels of Harm London NHS England \u201d(2023) https:\/\/www.england.nhs.uk\/long\u2010read\/policy\u2010guidance\u2010on\u2010recording\u2010patient\u2010safety\u2010events\u2010and\u2010levels\u2010of\u2010harm\/."},{"key":"e_1_2_11_24_1","unstructured":"Eli Lilly and Company Limited \u201cMounjaro KwikPen 2.5 mg Solution for Injection in Pre\u2010Filled Pen: Summary of Product Characteristics (SmPC) \u201dElectronic Medicines Compendium (eMC) (2025) https:\/\/www.medicines.org.uk\/emc\/product\/15481\/smpc."},{"key":"e_1_2_11_25_1","unstructured":"Ministry of Housing Communities and Local Government \u201cEnglish Indices of Deprivation 2025: Statistical Release London Ministry of Housing Communities and Local Government \u201d(2025) https:\/\/www.gov.uk\/government\/statistics\/english\u2010indices\u2010of\u2010deprivation\u20102025\/english\u2010indices\u2010of\u2010deprivation\u20102025\u2010statistical\u2010release."},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqaf028"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40618\u2010024\u201002441\u2010z"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13679\u2010017\u20100262\u2010y"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010024\u201003412\u2010w"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.2575"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/aogs.13326"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71067","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.71067","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71067","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:22:32Z","timestamp":1788409352000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/10.1111\/dom.71067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1111\/dom.71067"],"URL":"https:\/\/doi.org\/10.1111\/dom.71067","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"assertion":[{"value":"2026-03-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}